

# RECEIVED CENTRAL FAX CENTER

Eli Lilly and Company
Lilly Corporate Center
Indianapolis, IN 46285
(317) 276-2000

Patent Division

DEC 0 2 2005

TO:	FROM:	
	John A. Cleveland	
	Patent Attorney	
COMPANY:	DATE:	
USPTO	December 2, 2005	
FAX NUMBER:	FAX NUMBER:	
571-273-8300	(317) 276-3861	
PHONE NUMBER:	PHONE NUMBER:	
	(317) 276-0307	

URGENT MPER YOUR REQUEST □ FOR REVIEW □ PLEASE COMMENT □ PLEASE REPLY

#### **COMMENTS:**

RE: APPLICANTS: JULIE KAY BUSH

SERIAL NO. 10/520,360 FILING DATE: JULY 8, 2003 DOCKET NO.: X-14884 US

PRIVILEGED AND CONFIDENTIAL COMMUNICATION

If there are any problems with this transmittal, please call Valerie Wilson at (317) 433-6423.

This facsimile message is intended only for the individual to whom it is addressed and may contain information that is privileged, confidential or exempt from disclosure under applicable law. If you have received this facsimile in error, pleuse notify us immediately by telephone (collect), and return the original message to us at the above address via U.S. Postal Service.

#### RECEIVED **CENTRAL FAX CENTER**

CERTIFICATION OF FACSIMILE TRANSMISSION	DEC <b>0.2</b> 2005
I hereby certify that this paper is being facsimile transmitted to the Patent and Trademark Office on the date shown below.	
Type or print name of person signing certification	
Signature Datc	

### PATENT APPLICATION IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

First Applicant:

**BUSH Julie Kay** 

Group Art Unit: 1616

Serial No.:

10/520360

Examiner:

QAZI, SABIHA NAIM

Application Date: July 8, 2003

Conf No.: 5540

US Nat'l Entry

Date (if applicable): January 5, 2005

CRYSTALLINE 2,5-DIONE-3-(1-METHYL-1H-INDOL-3-YL)-4-[1-

(PYRIDIN-2-YLMETHYL)PIPERIDIN-4-YL]-1H-INDOL-3-YL]-1H-

PYRROLE MONO-HYDROCHLORIDE

Docket No.:

For:

X-14884

## RESPONSE TO NOTICE OF NON-COMPLIANT AMENDMENT UNDER SECTION 37 CFR 1.121

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

In response to a Notice of Non-Compliant Amendment dated November 4, 2005, Applicants submit the following amendments and remarks in connection with the above-identified patent application: